ATE492542T1 - Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas - Google Patents

Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas

Info

Publication number: ATE492542T1
Authority: AT; Austria
Prior art keywords: biphenyl; carbonylaminosic; obesitas; preparation; treatment
Prior art date: 2004-10-15

Application number

AT05812611T

Other languages

English (en)

Inventor

Roger Smith

Stephen O'connor

Philip Coish

Derek Lowe

Roger Clark

Jeffrey Stebbins

Ann-Marie Campbell

Christiana Akuche

Tatiana Shelekhin

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-15

Filing date

2005-10-14

Publication date

2011-01-15

2005-10-14 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE492542T1 publication Critical patent/ATE492542T1/de

Links

-1 BIPHENYL-4-YL Chemical class 0.000 title abstract 2
239000002253 acid Substances 0.000 title abstract 2
208000008589 Obesity Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT05812611T 2004-10-15 2005-10-14 Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas ATE492542T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61897504P	2004-10-15	2004-10-15
PCT/US2005/037215 WO2006044775A2 (en)	2004-10-15	2005-10-14	Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity

Publications (1)

Publication Number	Publication Date
ATE492542T1 true ATE492542T1 (de)	2011-01-15

Family

ID=36203612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05812611T ATE492542T1 (de)	2004-10-15	2005-10-14	Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas

Country Status (21)

Country	Link
US (2)	US7759376B2 (de)
EP (1)	EP1805156B1 (de)
JP (1)	JP2008516978A (de)
KR (1)	KR20070063546A (de)
CN (1)	CN101087769A (de)
AT (1)	ATE492542T1 (de)
AU (1)	AU2005295453A1 (de)
BR (1)	BRPI0516483A (de)
CA (1)	CA2583784A1 (de)
CR (1)	CR9034A (de)
DE (1)	DE602005025517D1 (de)
EA (1)	EA200700851A1 (de)
EC (1)	ECSP077397A (de)
ES (1)	ES2357015T3 (de)
IL (1)	IL182218A0 (de)
MA (1)	MA28935B1 (de)
MX (1)	MX2007004217A (de)
NO (1)	NO20072461L (de)
TN (1)	TNSN07111A1 (de)
WO (1)	WO2006044775A2 (de)
ZA (1)	ZA200703002B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ555683A (en)	2004-12-14	2010-09-30	Astrazeneca Ab	Oxadiazole derivatives as dgat inhibitors
AU2006318260B2 (en)	2005-11-21	2012-05-17	Anadys Pharmaceuticals, Inc.	Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
JP2009520786A (ja)	2005-12-22	2009-05-28	アストラゼネカアクチボラグ	Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン
KR101456721B1 (ko)	2006-03-31	2014-10-31	노파르티스 아게	신규 화합물
EP2041099A1 (de)	2006-05-30	2009-04-01	AstraZeneca AB	1,3,4-oxadiazolderivate als dgat1-inhibitoren
ATE492541T1 (de)	2006-05-30	2011-01-15	Astrazeneca Ab	Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
KR100795462B1 (ko)	2006-09-27	2008-01-16	한국생명공학연구원	인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100811100B1 (ko)	2006-09-27	2008-03-06	한국생명공학연구원	벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
AR063311A1 (es)	2006-10-18	2009-01-21	Novartis Ag	Compuestos organicos
EP2101783A2 (de) *	2006-12-11	2009-09-23	Novartis Ag	Verfahren zur vorbeugung oder behandlung von myokardischämie
JO2972B1 (en)	2007-06-08	2016-03-15	جانسين فارماسوتيكا ان. في	Piperidine / piperazine derivatives
RU2470017C2 (ru)	2007-06-08	2012-12-20	Янссен Фармацевтика Н.В.	Производные пиперидина/пиперазина
WO2008148851A1 (en) *	2007-06-08	2008-12-11	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
CA2687912C (en)	2007-06-08	2015-11-03	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
AR066169A1 (es)	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009081195A1 (en)	2007-12-20	2009-07-02	Astrazeneca Ab	Carbamoyl compounds as dgat1 inhibitors 190
EP2303270B1 (de)	2008-05-05	2017-05-17	Sanofi	Acylamino-substituierte kondensierte cyclopentan-carbonsäure-derivate und ihre verwendung als pharmazeutika
JP5579170B2 (ja)	2008-06-05	2014-08-27	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
US20100168079A1 (en) *	2008-12-23	2010-07-01	Daniela Angst	Biaryl Benzylamine Derivatives
EP2389366A1 (de) *	2009-01-23	2011-11-30	Msd K.K.	Benzodiazepin-2-on-derivate
DK3366686T3 (da)	2009-03-20	2020-11-23	Metabasis Therapeutics Inc	Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
US8268820B2 (en) *	2009-03-26	2012-09-18	Hoffmann-La Roche Inc.	2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
EP2411005A1 (de)	2009-03-27	2012-02-01	Bristol-Myers Squibb Company	Verfahren zur prävention von schwerwiegenden unerwünschten kardiovaskulären ereignissen mit dpp-iv-inhibitoren
MX2011014018A (es)	2009-06-19	2012-02-22	Astrazeneca Ab	Pirazincarboxamidas como inhibidores de dgati.
AR079022A1 (es)	2009-11-02	2011-12-21	Sanofi Aventis	Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
RU2012149806A (ru)	2009-11-05	2014-05-27	Пирамал Энтерпрайзис Лимитед	Карбоксиоксазольные или тиазольные соединения в качестве ингибиторов dgat-1, пригодные для лечения ожирения
CA2784308C (en) *	2009-12-16	2017-11-28	Pola Chemical Industries Inc.	Preventing or ameliorating agent for pigmentation
BR112012024618A2 (pt)	2010-03-30	2019-09-24	Novartis Ag	usos de inibidores de dgat1
KR101392334B1 (ko)	2011-05-03	2014-05-12	한국생명공학연구원	신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014039411A1 (en)	2012-09-05	2014-03-13	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (de)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
PL3174875T3 (pl) *	2014-08-01	2021-01-25	Bayer Pharma Aktiengesellschaft	Sposób wytwarzania (4S)-4-(4-cyjano-2-metoksyfenylo)-5-etoksy-2,8-dimetylo-1,4-dihydro-1,6-naftyrydyno-3-karboksyamidu i jego oczyszczanie do zastosowania jako aktywny składnik farmaceutyczny
CN105646510A (zh) *	2014-12-02	2016-06-08	重庆宁牧生态农业有限公司	一种用作抗肥胖剂的化合物
BR112020018790A2 (pt)	2018-03-16	2020-10-13	Anji Pharmaceuticals Inc.	composições e métodos para tratar constipação severa
US20220304984A1 (en) *	2019-06-12	2022-09-29	Vanderbilt University	Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) *	2020-10-19	2021-02-09	济南大学	一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en)	2021-11-11	2023-05-19	Koninklijke Nederlandse Akademie Van Wetenschappen	Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4164645B2 (ja) *	2002-08-09	2008-10-15	株式会社大塚製薬工場	Ｄｇａｔ阻害剤
US7244727B2 (en) *	2002-11-22	2007-07-17	Japan Tobacco Inc.	Fused bicyclic nitrogen-containing heterocycles
AR044152A1 (es) *	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

2005
- 2005-10-14 EA EA200700851A patent/EA200700851A1/ru unknown
- 2005-10-14 CN CNA2005800433280A patent/CN101087769A/zh active Pending
- 2005-10-14 BR BRPI0516483-4A patent/BRPI0516483A/pt not_active IP Right Cessation
- 2005-10-14 WO PCT/US2005/037215 patent/WO2006044775A2/en active Application Filing
- 2005-10-14 EP EP05812611A patent/EP1805156B1/de not_active Not-in-force
- 2005-10-14 MX MX2007004217A patent/MX2007004217A/es not_active Application Discontinuation
- 2005-10-14 US US11/665,317 patent/US7759376B2/en not_active Expired - Fee Related
- 2005-10-14 KR KR1020077008522A patent/KR20070063546A/ko not_active Application Discontinuation
- 2005-10-14 AT AT05812611T patent/ATE492542T1/de not_active IP Right Cessation
- 2005-10-14 JP JP2007536988A patent/JP2008516978A/ja active Pending
- 2005-10-14 ES ES05812611T patent/ES2357015T3/es active Active
- 2005-10-14 DE DE602005025517T patent/DE602005025517D1/de active Active
- 2005-10-14 AU AU2005295453A patent/AU2005295453A1/en not_active Abandoned
- 2005-10-14 CA CA002583784A patent/CA2583784A1/en not_active Abandoned
2007
- 2007-03-27 IL IL182218A patent/IL182218A0/en unknown
- 2007-03-28 TN TNP2007000111A patent/TNSN07111A1/en unknown
- 2007-03-30 CR CR9034A patent/CR9034A/es not_active Application Discontinuation
- 2007-04-12 ZA ZA200703002A patent/ZA200703002B/xx unknown
- 2007-04-13 EC EC2007007397A patent/ECSP077397A/es unknown
- 2007-04-17 MA MA29831A patent/MA28935B1/fr unknown
- 2007-05-14 NO NO20072461A patent/NO20072461L/no not_active Application Discontinuation
2010
- 2010-07-14 US US12/836,035 patent/US20110118302A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL182218A0 (en)	2007-09-20
DE602005025517D1 (de)	2011-02-03
MX2007004217A (es)	2007-06-11
US20070265298A1 (en)	2007-11-15
MA28935B1 (fr)	2007-10-01
ES2357015T3 (es)	2011-04-15
NO20072461L (no)	2007-07-03
EA200700851A1 (ru)	2007-12-28
ECSP077397A (es)	2007-05-30
JP2008516978A (ja)	2008-05-22
WO2006044775A3 (en)	2006-06-15
US7759376B2 (en)	2010-07-20
TNSN07111A1 (en)	2008-06-02
ZA200703002B (en)	2008-08-27
CN101087769A (zh)	2007-12-12
WO2006044775A2 (en)	2006-04-27
EP1805156B1 (de)	2010-12-22
KR20070063546A (ko)	2007-06-19
AU2005295453A1 (en)	2006-04-27
BRPI0516483A (pt)	2008-09-02
EP1805156A4 (de)	2009-06-10
CR9034A (es)	2008-11-18
US20110118302A1 (en)	2011-05-19
EP1805156A2 (de)	2007-07-11
CA2583784A1 (en)	2006-04-27

Legal Events

Date	Code	Title	Description
2011-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE492542T1 (de)	2011-01-15	Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
MXPA05012061A (es)	2006-02-22	Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
EA200900802A1 (ru)	2010-04-30	Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru)	2006-08-25	Способы и композиции для лечения амилоидных заболеваний
WO2007016538A3 (en)	2007-10-04	Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
DE602004020072D1 (de)	2009-04-30	1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE519488T1 (de)	2011-08-15	Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE395871T1 (de)	2008-06-15	Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
TW200730515A (en)	2007-08-16	N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE544748T1 (de)	2012-02-15	Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE447551T1 (de)	2009-11-15	Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602005021970D1 (de)	2010-08-05	Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
ATE432278T1 (de)	2009-06-15	Verbindungen zur behandlung von krankheiten
DE502005010499D1 (de)	2010-12-23	Implantat zur Behandlung von Fettsucht
ATE538651T1 (de)	2012-01-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE389395T1 (de)	2008-04-15	Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE602005018366D1 (de)	2010-01-28	Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
DE602005014632D1 (de)	2009-07-09	Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE602004021358D1 (de)	2009-07-16	Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE448779T1 (de)	2009-12-15	Methode zur behandlung trockener augen und uveitis
DE602005013287D1 (de)	2009-04-23	Zusammensetzung zur behandlung von leder
DE602005027228D1 (de)	2011-05-12	Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE361071T1 (de)	2007-05-15	Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE60322983D1 (de)	2008-09-25	Pflanzliche zusammensetzung zur behandlung von gastrointestinalen erkrankungen